Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTR-01 in Recessive Dystrophic Epidermolysis Bullosa
NCT04599881Phase 2Completed
- Sponsor
- Phoenix Tissue Repair
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of RIN-002 in Recessive Dystrophic Epidermolysis Bullosa (RDEB), sponsored by Phoenix Tissue Repair. Started Oct 2020; status: completed.
02
Drugs
RIN-002
03
Conditions
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NCT04599881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04599881.